Colchicine and CRP in Atrial Fibrillation and AF Ablation

Completed · Phase 2 · Has a placebo group

Conditions studied: Atrial Fibrillation

In brief

Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the rise in CRP which occurs following atrial fibrillation ablation

Key facts

Study ID

NCT01755949

Run by

Mayo Clinic

People needed

26

Starts

2013-03-01

Expected to finish

2016-12-06

Last updated by the study team

2019-05-09

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices. Diagnosis of AF will be made based on the 12 -lead surface ECG.
• Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the electrophysiology laboratory for the procedure in sinus rhythm..
• Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting in the electrophysiology laboratory in atrial fibrillation .

You may not qualify if…

• Abnormal liver function with elevated enzymes> 1.5 times the normal.
• Abnormal kidney function with glomerular filtration rate < 50 ml/min
• Increased levels of creatine kinase or known myopathy
• Neutropenia
• Known GI disorders
• Women of childbearing age who have not had surgical sterilization and are not using oral contraceptives, or who's spouse has not had surgical sterilization will be excluded due to the length of the trial and the possibility that they could become pregnant after entry.
• Pregnant and lactating women
• Lactose intolerance
• Known sensitivity, allergy, or contraindication to colchicine use

Where it is running

• Mayo Clinic Florida — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.